Firdaus, Fakiha
Kuchakulla, Manish
Qureshi, Rehana
Dulce, Raul Ariel
Soni, Yash
Van Booven, Derek J.
Shah, Khushi
Masterson, Thomas
Rosete, Omar Joel http://orcid.org/0000-0002-7735-5390
Punnen, Sanoj
Hare, Joshua M.
Ramasamy, Ranjith
Arora, Himanshu http://orcid.org/0000-0003-3143-6387
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 HL137355, 1R01 HL107110, 1R01 HL134558, R01 CA136387, 1R01DK130991-01, 1R01DK130991-01)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
American Cancer Society
U.S. Department of Health & Human Services | National Institutes of Health
Northeastern Section of the American Urological Association
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 6 July 2022
Revised: 16 September 2022
Accepted: 22 September 2022
First Online: 8 October 2022
Competing interests
: Authors declare that they have no competing interests. JMH reports having a patent for cardiac cell-based therapy and holds equity in Vestion Inc., and maintains a professional relationship with Vestion Inc. as a consultant and member of the Board of Directors and Scientific Advisory Board. Vestion Inc. did not play a role in the design, conduct, or funding of the study. JMH is the Chief Scientific Officer, a compensated consultant, and a board member for Longeveron Inc. and holds equity in Longeveron. JMH is also the co-inventor of intellectual property licensed to Longeveron. Longeveron did not play a role in the design, conduct, or funding of the study. The University of Miami is an equity owner in Longeveron Inc., which has licensed intellectual property from the University of Miami.